Baricitinib for the treatment of rheumatoid arthritis

Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food an...

Full description

Saved in:
Bibliographic Details
Main Authors: Ivan Urits, Jacob Israel, Hayk Hakobyan, George Yusin, Grace Lassiter, Nathan Fackler, Amnon A. Berger, Hisham Kassem, Alan Kaye, Omar Viswanath
Format: article
Language:EN
Published: Termedia Publishing House 2020
Subjects:
R
Online Access:https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA. This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.